← Leaderboards
Megan Yates
University Of Pittsburgh At Pittsburgh
$248,564
Attributed
$248,564
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54K · FY2020–24$100K$75K$50K$25K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$248,564 · 1
By mechanism
F30$248,564 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Surinder Kumar Batra$34,830,369
- Matthew S Freiberg$20,071,860
- Boris Birmaher$42,923,930
- Alison Morris$31,399,077
- Joanne L. Flynn$43,717,509
Others in their field
Other Emerging Leaders on “Chimeric Proteins”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,733,385
- Neil King · University Of Washington$9,764,305
- Sunil Kannanganat Sidharthan · Astero Erado Inc$5,289,481
- Jarrod Mousa · University Of Georgia$4,688,589
- Joana M Murad · Celdara Medical, Llc$4,659,089
Research focus
Chimeric ProteinsAdvanced Breast CancerAlternative TreatmentCessation Of LifeAromatase InhibitorsBiopsy SpecimenBloodBindingBiological MarkersBreast Cancer Cell LineBiologyBreast Cancer DiagnosisBreast Cancer ModelBreast Cancer PatientCancer Cell GrowthCancer EtiologyBlood SpecimenCandidate Disease GeneBreast Cancer CellCell GrowthCell LineCell ProliferationCellsChip-Seq
Grant awards (5)
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast Cancer$53,974
F30 · FY2024 · CA · contact PI
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast Cancer$52,694
F30 · FY2023 · CA · contact PI
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast Cancer$47,948
F30 · FY2022 · CA · contact PI
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast Cancer$47,232
F30 · FY2021 · CA · contact PI
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast Cancer$46,716
F30 · FY2020 · CA · contact PI